Magnetic Resonance Study of Liver in Chemotherapy

Sponsor
Memorial Sloan Kettering Cancer Center (Other)
Overall Status
Completed
CT.gov ID
NCT00578838
Collaborator
(none)
55
1
117
0.5

Study Details

Study Description

Brief Summary

The purpose of this study is to see whether magnetic resonance (MR) techniques can detect changes caused by chemotherapy in the livers of patients who have been treated for colorectal cancer. Some patients who undergo chemotherapy for colorectal cancer may experience side-effects in their livers. These side effects may influence further treatment options. If this study finds that MR techniques detect changes in the liver due to chemotherapy, then MR methods may eventually be used to help patients and physicians plan further treatment.

Condition or Disease Intervention/Treatment Phase
  • Other: Magnetic Resonance
  • Other: Magnetic Resonance

Detailed Description

Each patient will have 4 MR exams: prior to or within one week of the start of the chemotherapy regimen, one after 6 weeks of chemotherapy, a third after completion of chemotherapy (between 12 and 24 weeks post-initiation of chemotherapy) and a long term followup study at least 4 months after the completion of chemotherapy. Normal volunteers will be recruited and studied by MR for comparison to patient data.

Study Design

Study Type:
Observational
Actual Enrollment :
55 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Magnetic Resonance Study of Liver in Chemotherapy
Study Start Date :
Aug 1, 2006
Actual Primary Completion Date :
May 1, 2016
Actual Study Completion Date :
May 1, 2016

Arms and Interventions

Arm Intervention/Treatment
1

25 patients with metastatic colorectal cancer. Each patient will have 4 MR exams: prior to or within one week of the start of the chemotherapy regimen, one after 6 weeks of chemotherapy, a third after completion of chemotherapy (between 12 and 24 weeks post-initiation of chemotherapy) and a long term followup study at least 4 months after the completion of chemotherapy.

Other: Magnetic Resonance
Patients each will undergo 4 MR examinations as part of this research study.

2

25 patients with non-metastatic colorectal cancer. Each patient will have 4 MR exams: prior to or within one week of the start of the chemotherapy regimen, one after 6 weeks of chemotherapy, a third after completion of chemotherapy (between 12 and 24 weeks post-initiation of chemotherapy) and a long term followup study at least 4 months after the completion of chemotherapy.

Other: Magnetic Resonance
Patients each will undergo 4 MR examinations as part of this research study.

3

11 healthy volunteers, who will also undergo two scans 2-3 weeks apart.

Other: Magnetic Resonance
You will have two MR exams on two different days. There will be no injection of contrast material. An MR exam requires about 1 hour. The second MR exam will take place 2-3 weeks after the first one. This second MR exam will take about 1 hour and will look at whether the results from the MR exams are reliable and repeatable.

Outcome Measures

Primary Outcome Measures

  1. To determine whether magnetic resonance techniques can detect changes in normal liver morphology and metabolism caused by chemotherapy in patients with colorectal cancer. [2 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Provide written informed consent.

  • 21 years of age or older.

  • Histologically confirmed diagnosis of colorectal carcinoma (patients only).

  • Resected primary colorectal cancer and no metastatic disease or primary colorectal cancer with no metastatic disease and planned resection after neo-adjuvant chemotherapy or metastatic colorectal carcinoma considered by the attending physician to have resectable or potentially resectable hepatic metastases (patients only). Each patient will be staged by his/her attending physician in the Department of Medicine or Surgery. Hepatic metastases are considered resectable if they are expected to be completely removable with negative margins by a procedure that leaves behind sufficient liver parenchyma with arterial/portal blood supply, venous drainage and biliary drainage for subsequent regeneration and survival. Potentially resectable indicates that a reduction in tumor size due to chemotherapy could render the tumors resectable.

Exclusion Criteria:
  • Inability to cooperate for an MR exam.

  • Contraindication to MR:

  • Pacemaker

  • Aneurysmal clips

  • Any ferrous metallic implants which could be deflected by the magnet

  • Metal implants in field of view which could distort the images and spectroscopy data

  • Pregnant women

  • Age and mental status wherein he/she is unable to cooperate for MR study

  • Patients who are considered to have unresectable hepatic metastases will be excluded. Hepatic metastases are considered unresectable if their removal would leave behind insufficient liver parenchyma for subsequent regeneration and survival. In addition, hepatic metastases are considered unresectable if their removal would be expected to leave behind residual disease (positive margins). Also, patients are considered unresectable if they have any comorbid conditions which would jeopardize successful recovery from hepatic resection.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Memorial Sloan Kettering Cancer Center New York New York United States 10065

Sponsors and Collaborators

  • Memorial Sloan Kettering Cancer Center

Investigators

  • Principal Investigator: Kristen Zakian, PhD, Memorial Sloan Kettering Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00578838
Other Study ID Numbers:
  • 06-082
First Posted:
Dec 21, 2007
Last Update Posted:
May 9, 2016
Last Verified:
May 1, 2016
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 9, 2016